H 29051

Drug Profile

H 29051

Latest Information Update: 24 Jun 2002

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Hassle Lakemedel
  • Class Anti-ischaemics
  • Mechanism of Action Lipid peroxidation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Myocardial ischaemia

Most Recent Events

  • 22 Aug 2000 Astra Hässle is now called Hässle Läkemedel
  • 07 Apr 1999 Merger of Astra and Zeneca to form AstraZeneca completed
  • 04 Aug 1998 A study has been added to the Ischaemic Heart Disease pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top